The drug increases the body’s resistance to the effects of various damaging factors (shock, hypoxia, ischemia, injury, cerebrovascular accident, activating energosinteziruyuschie improving mitochondrial function and energy metabolism in cells.
The mechanism of action is due to the ability to enhance the compensatory activation of aerobic glycolysis, reduce the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with increasing deca durabolin cycle the content of ATP (adenosine triphosphate) and creatine phosphate and the stabilization of cell membranes. Improves and stabilizes the brain metabolism and blood flow to the brain, improves the rheological properties of blood, inhibits platelet aggregation. Has a modulating effect in relation athrombogenic properties of vascular endothelium and contributes to the improvement of brain perfusion characteristics. While taking improves memory performance. It has anxiolytic effects, eliminates anxiety, fear, stress, anxiety. It has hypolipidemic effect, reduces total cholesterol and low density lipoprotein.
In single and exchange application Meksidanta ® maximum plasma concentration (C max ) is achieved in 0.58 hours at a dose of 400-500 mg C. Max in plasma – 3.5-4 ug / ml. Quickly spread to organs and tissues. The average retention time of the drug – 0.7-1.3 hours. Meanwhile Meksidant ® rapidly cleared from plasma and after 4 hours practically defined therein.
The pharmacokinetic profiles were not significantly different in both single and under constant introduction. Excreted in the urine as unchanged form or in the form glyukuronkonyugatov.
Identification of metabolites of 5: 1 is produced in the liver metabolite minutes – 3-phosphate oksiiiridina -which in the blood under the influence of alkaline phosphatase decomposed into phosphoric acid and 3-hydroxypyridin; 2nd metabolite produced in large quantities and is found in the urine of 1-2 knots administration is pharmacologically active; 3rd metabolite also displays in large amounts in the urine; 4 th and 5 th metabolites are glyukuronkonyugaty.
Indications for use :
Meksidant ® administered as part of combination therapy with:
- acute ischemic stroke,
- traumatic brain injury,
- vascular encephalopathy,
- vegetative-vascular dystonia,
- neurotic disorders with anxiety syndrome,
- intellectual-mental disorders of various origins (including memory impairment in the elderly)
- relief of withdrawal symptoms of alcoholism to the presence in the clinical picture of neurotic and vegetative-vascular disorders.
acute human liver and kidneys, increased sensitivity to “drug or intolerance to the drug, pregnancy, lactation, children’s age.
Allergic diseases in history.
Dosage and administration .
Deca durabolin cycleadministered as part of combination therapy intramuscularly or intravenously (bolus or infusion). Doses picked individually. Started treatment with doses of 50-100 mg, 1-3 times a day, gradually increasing the dose to produce a therapeutic effect. The duration of treatment and the selection of individual dose depends on the severity of the patient’s condition and the effectiveness of treatment. The maximum daily dose of 800 mg. Chip is administered for 5-7 minutes. For infusion administration of the drug is diluted in 200 ml of physiological 0.9% sodium chloride solution, drip – at a rate of 60 drops per minute. In the treatment of acute stroke is administered in the first 7-8 days at a dose of 200-300 mg 1 time day intravenously (drip), as ” the intramuscular injection of 100 mg three times a day. When traumatic lesions of the central nervous system is administered intravenously (drip) 400-600 mg dose per day for 7-8 days, followed by a continuation of the treatment intramuscular injection of 300 mg per day for 10-14 days. in vascular encephalopathy in a phase of decompensation administered by intravenous bolus or infusion, at a dose of 100 mg 1 time a day for 14 days. Then, the drug is administered by intramuscular injection of 100 mg 2-3 times a day for the next 14 days. For the prevention of vascular encephalopathy is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days. In the intellectual-mental and cognitive disorders, drug administered intramuscularly in the dose of 100-300 mg per day for 14 days. atwithdrawal syndrome deca durabolin cycle is administered at a dose of 100-200 mg intramuscularly, 2-3 times a day or intravenously (drip) 1-2 times a day. If neurological disorders and of vascular dystonia drug administered intramuscularly at a dose of 50-400 mg per day for 14 days.
Side effect . From the digestive system : rarely – nausea, dry mouth, diarrhea. On the part of the central nervous system : rarely – drowsiness. Allergic reactions. For parenteral administration (particularly in / jet) : dry, “metallic” aftertaste in the mouth. feelings “bottled heat” in the body, bad breath, sore throat and discomfort in the chest, feeling short of breath (usually associated with extremely high injection speed and are of short duration); long-term use – nausea, flatulence; sleep disturbances (drowsiness or disturbance of sleep).
Overdose . Symptoms : sleep disorders (insomnia, in some cases – drowsiness); . with a / in the introduction -neznachitelnoe and short-term (up to 1.5-2 hours), high blood pressure treatment : as a rule, does not require – the symptoms disappear on their own within a day. In severe cases of insomnia – nitrazepam 10 mg, 10 mg of oxazepam or diazepam 5mg. Excessive increase in blood pressure – antihypertensive drugs for blood pressure control.
Interaction with other drugs .
When a combination of the application increases the effects of anticonvulsants (carbamazepine), tranquilizers (bromdigidrohlorfenilbenzodiazepin, diazepam), antiparkinsonian agents (levodopa).It reduces the toxic effects of ethanol.
Special instructions .
At the beginning of treatment should refrain from activities potentially hazardous activities that require high concentration and psychomotor speed reactions. Currently available a number of drugs with the same active ingredient emoxypine that should be considered during treatment of other diseases, the treatment of which can be used drugs with a given substance. gp test enanth 250